Business Information
The group's principal activity is to discover, develop and commercialize novel small molecule drugs principally to treat metabolic diseases. The diseases treated are diabetes, hyperlipidemia, cholesterol, and obesity. The product candidates in clinical trials are cs-917, remofovir and mb07133, indicated for the treatment of type 2 diabetes, hepatitis b and primary liver cancer, respectively. The group also have research programs focused on metabolic diseases linked to pathways in the liver such as type 2 diabetes, hyperlipidemia and obesity, as well as liver diseases such as hepatitis c and liver fibrosis.
|
|
Name |
Title
|
Email
|
| David Hale | Chmn. | N/A | | John Beck | CFO, Sr. VP - Finance | N/A | | Constance Bienfait | VP - Investor Relations, Corporate Communications | Available | | Edgardo Baracchini | Sr. VP - Business Development | Available | | Howard Foyt | VP - Clinical Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 4,386 | (33,268) | | 2005 | 3,771 | (23,580) | | 2004 | 6,837 | (14,972)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
